Document Detail

[Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
MedLine Citation:
PMID:  22117740     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy.
METHODS: A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snelleńs method and the foveal thickness, before and after the injection.
RESULTS: The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431 ± 0.249 vision lines and after was 0.631 ± 0.310 vision lines (P=.017).The foveal thickness was 351.25 ± 78.492 μm and after treatment was 183.50 ± 22.640 μm (P=.012).
CONCLUSIONS: Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography.
I Gregori-Gisbert; F Aguirre-Balsalobre; J García-Sánchez; G León-Salvatierra; E Mengual-Verdú; J R Hueso-Abancéns
Publication Detail:
Type:  Clinical Trial; English Abstract; Journal Article     Date:  2011-10-11
Journal Detail:
Title:  Archivos de la Sociedad Española de Oftalmología     Volume:  86     ISSN:  1989-7286     ISO Abbreviation:  Arch Soc Esp Oftalmol     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-28     Completed Date:  2012-04-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  1304603     Medline TA:  Arch Soc Esp Oftalmol     Country:  Spain    
Other Details:
Languages:  spa     Pagination:  407-11     Citation Subset:  IM    
Copyright Information:
2010 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.
Servicio de Oftalmología, Hospital Clínico Universitario San Juan de Alicante, España.
Vernacular Title:
Coriorretinopatía serosa central recidivante y crónica. Estudio del espesor retiniano al mes del tratamiento con una inyección de bevacizumab intravítreo.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage,  therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage,  therapeutic use*
Central Serous Chorioretinopathy / drug therapy*,  pathology
Chronic Disease
Intravitreal Injections
Macula Lutea / pathology
Middle Aged
Retina / pathology*
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intermittent exotropia: bilateral lateral rectus recession treatment and long term results.
Next Document:  [Endogenous endophthalmitis as a first clinical manifestation of Klebsiella sepsis. The importance o...